Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 59 resultados
LastUpdate Última actualización 17/01/2026 [07:42:00]
pdfxls
Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days
previousPage Resultados 50 a 59 de 59  

HYPERSPECTRAL IMAGING FOR EARLY DETECTION OF ALZHEIMER'S DISEASE

NºPublicación:  US2025359753A1 27/11/2025
Solicitante: 
REGENTS OF THE UNIV OF MINNESOTA [US]
REGENTS OF THE UNIVERSITY OF MINNESOTA
US_2025359753_PA

Resumen de: US2025359753A1

Described herein is the use of a visible near infrared (VNIR) hyperspectral imaging system as a non-invasive diagnostic tool for early detection of Alzheimer's disease (AD). Also described herein is the use of a VNIR hyperspectral imaging system in high throughput screening of potential therapeutics against AD.

SPATIAL MRNA/PROTEIN CO-ASSAYS USING APTAMERS

NºPublicación:  US2025361504A1 27/11/2025
Solicitante: 
ILLUMINA INC [US]
ILLUMINA, INC
US_2025361504_PA

Resumen de: US2025361504A1

The present disclosure relates, in general, to methods of preparing a spatial proteome and/or transcriptome sequencing library. The spatial proteome and/or transcriptome sequencing library from a biological sample is useful, in some aspects, to determine a genetic profile and help diagnose a subject who has or is at risk of having a disorder, and improve treatment of the subject.

マススペクトロメトリーによるアポリポタンパク質Eアイソタイプの検出

NºPublicación:  JP2025172848A 26/11/2025
Solicitante: 
クエストダイアグノスティックスインヴェストメンツエルエルシー
JP_2025172848_PA

Resumen de: US2025191903A1

Provided are methods for determining the apolipoprotein E (ApoE) phenotype in a sample by mass spectrometry; wherein the ApoE allele(s) present in the sample is determined from the identity of the ions detected by mass spectrometry. In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.

METHOD OF MANUFACTURING BIOSENSOR FOR DETECTING BIOMARKER OF ALZHEIMER'S DISEASE AND BIOSENSOR MANUFACTURED THEREFROM

NºPublicación:  EP4652451A1 26/11/2025
Solicitante: 
NOVASCOPE BIOCHIPS INC [US]
Novascope Biochips Inc
KR_20250135778_PA

Resumen de: CN120457337A

The present disclosure provides a method of preparing a biosensor for detecting Alzheimer's disease biomarkers, comprising depositing an alumina film on a Si substrate by an atomic layer deposition system to form an Al2O3/Si substrate; depositing an electric contact part Cr/Au on the Al2O3/Si substrate through a thermal evaporator, and forming a source electrode, a drain electrode and a planar grid electrode on the Al2O3/Si substrate; providing double-layer graphene on the Al2O3/Si substrate through thermal annealing in a vacuum environment; performing low-damage plasma treatment (LDPT) on the double-layer graphene with a mixture of oxygen and hydrogen to form a graphene oxide/graphene (GO/G) layered composite material on the Al2O3/Si substrate; an antibody is immobilized on the surface of a GO/G layered composite material by a reaction between an amine group of the antibody and a carboxyl group of GO of the GO/G layered composite material, where the antibody is specific for p-tau217 protein.

METHOD FOR DETECTING A TAU PROTEIN FRAGMENT IN A SAMPLE

NºPublicación:  US2025355001A1 20/11/2025
Solicitante: 
GTINVENT LTD [GB]
GTINVENT LIMITED
JP_2025504410_PA

Resumen de: US2025355001A1

The invention relates to an in vitro method for detecting a tau protein fragment in a sample from a patient wherein the amino acid sequence of the fragment consists of amino acid residues within residues 113 to 379 of SEO ID NO: 1. The method may use a specific binding molecule, such as an antibody, directed to key epitopes of tau. The invention may find applications in diagnostics of tauopathics.

IDENTIFICATION OF TDP-43 CRYPTIC EXON-ENCODED NEOEPITOPES AS FUNCTIONAL FLUID BIOMARKERS FOR ALZHEIMER'S DISEASE AND RELATED DEMENTIA

NºPublicación:  US2025355002A1 20/11/2025
Solicitante: 
THE JOHNS HOPKINS UNIV [US]
The Johns Hopkins University
WO_2023245063_PA

Resumen de: US2025355002A1

The invention provides antibodies and binding fragments thereof that specifically binds to TDP-43 cryptic exon-encoded neoepitopes, and methods of use thereof. The methods of use include methods of detecting TDP-43 loss of function, methods of detection and/or diagnosing TDP-43 associated diseases, and methods of monitoring disease progression and/or response to therapy. The invention also provides a kit including the antibodies and binding fragments thereof.

COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND/OR TREATMENT OF AMYLOID B PEPTIDE PROTEINOPENIA VIA NEPRILYSIN INHIBITION

NºPublicación:  WO2025240658A1 20/11/2025
Solicitante: 
LVIS REGAIN LP [US]
LVIS-REGAIN LP
WO_2025240658_A1

Resumen de: WO2025240658A1

Neprilysin inhibitors are used for the treatment of patients with Alzheimer's disease or other proteinopenic diseases of the CNS. The patients selected for therapy may be selected based on confirmed biomarker diagnosis of disease, along with a reduced Aβ level.

METHODS AND COMPOSITIONS FOR SCREENING AND TREATING ALZHEIMER'S DISEASE

NºPublicación:  EP4649317A2 19/11/2025
Solicitante: 
POPULATION BIO INC [US]
Population Bio, Inc
US_2024310389_PA

Resumen de: US2024310389A1

This document provides methods and materials related to screening for and treating Alzheimer's disease (AD), including late-onset Alzheimer's disease (LOAD).

作为认知能力下降进展到阿尔茨海默病的速度的标志物的U-p53肽

Nº publicación: CN120981196A 18/11/2025

Solicitante:

戴尔戴莫股份公司

CN_120981196_PA

Resumen de: WO2024148357A2

U-p53 peptide P1 is useful in the determination of the rate of progression of Alzheimer's disease (AD). By quantitating the level of U-p53 peptides in a subject's biological sample, the rate of progression of Alzheimer's disease at the pre-clinical and prodromal stages of the disease in a subject can be determined.

traducir